J&J's Tecvayli-Darzalex Combo Shows 90% Reduction in Myeloma Progression
JNJ sits 56% above its 52-week low of $174.83 on light trading volume (0.1× avg).
Summary
J&J released late-stage data showing its Tecvayli plus Darzalex Faspro combination significantly improved overall survival in relapsed/refractory multiple myeloma. The 90% reduction in progression risk and 87% of patients achieving mortality risk comparable to the general population are striking efficacy signals. A new model-based analysis further supports the potential of Tecvayli plus Darzalex Faspro. This follows the July 23 report on Tecvayli plus Talvey, but this is a different combination with new survival data. The data could support earlier-line use and expand J&J's multiple myeloma franchise, which is a key growth area. Watch for regulatory submissions and potential label expansion.
At the time of this announcement, JNJ was trading at $272.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $655.8B. The 52-week trading range was $174.83 to $281.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.